Allianz Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Allianz Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-114,659	Closed	-$2.63M	–	2742
2018 Q1	$2.63M	Sell	114,659 -1,697	-1%	-$37.7K	﹤0.01%	1800
2017 Q4	$3.01M	Sell	116,356 -2,710	-2%	-$54.6K	﹤0.01%	1843
2017 Q3	$1.76M	Sell	119,066 -684	-0.6%	-$9.93K	﹤0.01%	2054
2017 Q2	$1.67M	Sell	119,750 -1,422	-1%	-$21K	﹤0.01%	2045
2017 Q1	$2.07M	Sell	121,172 -4,956	-4%	-$59.4K	﹤0.01%	1983
2016 Q4	$1.3M	Sell	126,128 -21,719	-15%	-$198K	﹤0.01%	2132
2016 Q3	$1.5M	Sell	147,847 -12,121	-8%	-$132K	﹤0.01%	2092
2016 Q2	$1.8M	Buy	159,968 +7,918	+5%	+$101K	﹤0.01%	1972
2016 Q1	$2.08M	Sell	152,050 -12,023	-7%	-$173K	﹤0.01%	1797
2015 Q4	$3.11M	Sell	164,073 -28,137	-15%	-$611K	﹤0.01%	1529
2015 Q3	$3.61M	Buy	+192,210	New	+$3.27M	﹤0.01%	1405

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Allianz Asset Management's CNCE Position: Q2 2018 in Review

Allianz Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2018, closing a stake of 114,659 shares — an estimated $2.63M sold.

Allianz Asset Management first reported a position in CNCE in Q3 2015 and held it in 11 quarters. The position peaked at $3.61M in Q3 2015. 120 funds tracked by Wall St. Rank hold CNCE as of Q2 2018.

Allianz Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Allianz Asset Management sold 114,659 Concert Pharmaceuticals, Inc. shares in Q2 2018, an estimated $2.63M.
Allianz Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 11 quarters.
Allianz Asset Management's Concert Pharmaceuticals, Inc. position peaked at $3.61M in Q3 2015.
120 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2018.

Based on Allianz Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.